CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Pharmaceutical Technology
Original article

EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168

RegulatorypositiveC-CAR168Positive
AI Analysis

Summary

AbelZeta Pharma's C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy, has received PRIME designation from the EMA's CHMP, expediting its regulatory pathway.

Outcome Details

PRIME designation granted by EMA CHMP

Importance:6/10
Sentiment:
0.75
EMAPRIMECAR-Tregulatory

Read the original article

Published by Pharmaceutical Technology on July 21, 2026 9:08 AM

Read Original